These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 23736536

  • 1. CRYAB modulates the activation of CD4+ T cells from relapsing-remitting multiple sclerosis patients.
    Quach QL, Metz LM, Thomas JC, Rothbard JB, Steinman L, Ousman SS.
    Mult Scler; 2013 Dec; 19(14):1867-77. PubMed ID: 23736536
    [Abstract] [Full Text] [Related]

  • 2. miR-15a and 16-1 are downregulated in CD4+ T cells of multiple sclerosis relapsing patients.
    Lorenzi JC, Brum DG, Zanette DL, de Paula Alves Souza A, Barbuzano FG, Dos Santos AC, Barreira AA, da Silva WA.
    Int J Neurosci; 2012 Aug; 122(8):466-71. PubMed ID: 22463747
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Differential effects of interferon-β1b on cytokine patterns of CD4+ and CD8+ T cells derived from RRMS and PPMS patients.
    Skrzipek S, Vogelgesang A, Bröker BM, Dressel A.
    Mult Scler; 2012 May; 18(5):674-8. PubMed ID: 22025329
    [Abstract] [Full Text] [Related]

  • 5. Dopamine favors expansion of glucocorticoid-resistant IL-17-producing T cells in multiple sclerosis.
    Ferreira TB, Barros PO, Teixeira B, Cassano T, Centurião N, Kasahara TM, Hygino J, Vasconcelos CC, Filho HA, Alvarenga R, Wing AC, Andrade RM, Andrade AF, Bento CA.
    Brain Behav Immun; 2014 Oct; 41():182-90. PubMed ID: 24882215
    [Abstract] [Full Text] [Related]

  • 6. Altered naive CD4 and CD8 T cell homeostasis in patients with relapsing-remitting multiple sclerosis: thymic versus peripheral (non-thymic) mechanisms.
    Duszczyszyn DA, Beck JD, Antel J, Bar-Or A, Lapierre Y, Gadag V, Haegert DG.
    Clin Exp Immunol; 2006 Feb; 143(2):305-13. PubMed ID: 16412055
    [Abstract] [Full Text] [Related]

  • 7. Anti-IL-16 therapy reduces CD4+ T-cell infiltration and improves paralysis and histopathology of relapsing EAE.
    Skundric DS, Dai R, Zakarian VL, Bessert D, Skoff RP, Cruikshank WW, Kurjakovic Z.
    J Neurosci Res; 2005 Mar 01; 79(5):680-93. PubMed ID: 15682385
    [Abstract] [Full Text] [Related]

  • 8. Secondary progressive in contrast to relapsing-remitting multiple sclerosis patients show a normal CD4+CD25+ regulatory T-cell function and FOXP3 expression.
    Venken K, Hellings N, Hensen K, Rummens JL, Medaer R, D'hooghe MB, Dubois B, Raus J, Stinissen P.
    J Neurosci Res; 2006 Jun 01; 83(8):1432-46. PubMed ID: 16583400
    [Abstract] [Full Text] [Related]

  • 9. Monocyte-derived HLA-G acts as a strong inhibitor of autologous CD4 T cell activation and is upregulated by interferon-beta in vitro and in vivo: rationale for the therapy of multiple sclerosis.
    Mitsdoerffer M, Schreiner B, Kieseier BC, Neuhaus O, Dichgans J, Hartung HP, Weller M, Wiendl H.
    J Neuroimmunol; 2005 Feb 01; 159(1-2):155-64. PubMed ID: 15652415
    [Abstract] [Full Text] [Related]

  • 10. The role of fractalkine (CX3CL1) in regulation of CD4(+) cell migration to the central nervous system in patients with relapsing-remitting multiple sclerosis.
    Blauth K, Zhang X, Chopra M, Rogan S, Markovic-Plese S.
    Clin Immunol; 2015 Apr 01; 157(2):121-32. PubMed ID: 25596452
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. CRYAB promoter polymorphisms: influence on multiple sclerosis susceptibility and clinical presentation.
    Stoevring B, Frederiksen JL, Christiansen M.
    Clin Chim Acta; 2007 Jan 01; 375(1-2):57-62. PubMed ID: 17010329
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Immunoglobulin-like transcript 3, an inhibitor of T cell activation, is reduced on blood monocytes during multiple sclerosis relapses and is induced by interferon beta-1b.
    Jensen MA, Yanowitch RN, Reder AT, White DM, Arnason BG.
    Mult Scler; 2010 Jan 01; 16(1):30-8. PubMed ID: 20007427
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS?
    Bar-Or A, Fawaz L, Fan B, Darlington PJ, Rieger A, Ghorayeb C, Calabresi PA, Waubant E, Hauser SL, Zhang J, Smith CH.
    Ann Neurol; 2010 Apr 01; 67(4):452-61. PubMed ID: 20437580
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.